~~<i id='E65E755F0F'><strike id='E65E755F0F'><tt id='E65E755F0F'><pre id='E65E755F0F'></pre></tt></strike></i>~~

Home» explore» comprehensive

comprehensive

author：Wikipedia 2025-10-04 07:23:04 Page View：4412

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Annovis Bio delivers candor, but not confidence, on Parkinson’s study
Next article： As demand for Covid shots wanes, Moderna seeks its next success

leisure time

United colonoscopy coverage change 'may cost lives,' doctors say

AdobeWhengastroenterologistslearnedinMarchthatUnitedHealthcareplanstobarricademanycolonoscopiesbehin

N.Y. state detects polio case, first in the U.S. since 2013

Poliovirusescancomefromtheoralpoliovaccineusedinanumberofcountries,butnottheUnitedStates.CDC/Dr.Jose

Medical records are filled with copy

AdobeIrecentlytookcareofapatientwhosemedicalrecordsincludedmultiplenotesaboutherpastopen-heartsurger

Alabama IVF ruling threatens families facing fatal genetic disease

Henrywithhisparents.Illustration:STAT;Courtesy:AllenGoldbergWhenmywife,Laurie,completedherninthinvit